Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection
https://doi.org/10.52667/2712-9179-2022-2-1-89-97
Abstract
Schizophrenia is a common and socially significant mental disorder that requires long-term use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes and of Aps transport across the blood-brain barrier (BBB) and the cell membrane of APs target neurons in the brain. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. The aim of the case report is to present the experience of using PGx in a 36-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.
Keywords
Supporting agencies: This study did not receive external funding.
About the Authors
L. P. Linova
P.P. Kashchenko Psychiatric Hospital N1
Russian Federation
Russian Federation
Lidia P. Linova
188357 Nikolskoe, St. Petersburg; ; tel.: +79117502396
A. A. Torgovtsev
P.P. Kashchenko Psychiatric Hospital N1
Russian Federation
Russian Federation
Anton A. Torgovtsev
188357 Nikolskoe, St. Petersburg
O. V. Limankin
P.P. Kashchenko Psychiatric Hospital N1
Russian Federation
Russian Federation
Oleg V. Limankin
188357 Nikolskoe, St. Petersburg
R. F. Nasyrova
P.P. Kashchenko Psychiatric Hospital N1; V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
Regina F. Nasyrova
188357 Nikolskoe, St. Petersburg; Saint Petersburg 192019
References
1. Katona, L.; Bitter, I.; Czobor, P. A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials? Transl Psychiatry 2021, 11(1), 510. doi: 10.1038/s41398-021-01636-9.
2. Kaar, S.J.; Natesan, S.; McCutcheon, R.; Howes, O.D. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 2020, 172, 107704. doi: 10.1016/j.neuropharm.2019.107704.
3. Kravtsov, V.V.; Filippov, I.A.; Vaiman, E.E.; Shnayder, N.A.; Nasyrova, R.F. Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2020, 120(7), 134-141. (In Russ.). https://doi.org/10.17116/jnevro2020120071134.
4. Nasyrova, R.F.; Schnaider, N.A.; Mironov, K.O.; Shipulin, G.A.; Dribnokhodova, O.P.; Golosov, E.A.; Tolmachev, M.Yu; Andreev, B.V.; Kurylev, A.A.; Akhmetova, L.Sh.; Limankin, O.V.; Neznanov, N.G. Pharmacogenetics of schizophrenia in real clinical practice: a clinical case. Neurology, Neuropsychiatry, Psychosomatics 2018, 10(4), 88–93. https://elibrary.ru/item.asp?id=36547318.
5. Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Oxidation of Antipsychotics. Encyclopedia 2022.
6. Dahl, M.L. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002, 41(7), 453-70. doi: 10.2165/00003088-200241070-00001.
7. Nasyrova, R.F.; Dobrodeeva, V.S.; Scopin, S.D.; Shnayder, N.A.; Neznanov, N.G. Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation. Bulletine of Psychiatry, Neurology and Neurosurgery 2020, 3, 6-8. (In Russ.). https://doi.org/10.33920/med-01-2003-01.
8. Ayano, G. Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 1A2 Enzyme and Relevant Drug Interactions: Review of Articles. Austin J Pharmacol Ther 2016, 4(2), 1085. doi: 10.4172/2167-065X.1000162.
9. Bahar, M.A.; Setiawan, D.; Hak, E.; Wilffert, B. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics 2017, 8(7), 701-739. doi: 10.2217/pgs-2017-0194.
10. Ayano, G. Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 2D6 Enzyme and Relevant Drug Interactions. Clin Pharmacol Biopharm 2016, 5, 162. doi: 10.4172/2167-065X.1000162.
11. Zhou, S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008, 9(4), 310-22. doi: 10.2174/138920008784220664.
12. Thomas, С.; Tampé, R. Structural and Mechanistic Principles of ABC Transporters. Annual Review of Biochemistry 2020, 89(1), 605-636. doi: 10.1146/annurev-biochem-011520-105201.
13. Alemayehu, D.; Melisie, G.; Taye K.; Tadesse E. The Role of ABC Efflux Transporter in Treatment of Pharmaco-Resistant Schizophrenia: A Review Article. Clin Pharmacol Biopharm 2019, 8, 189.
14. Carvalho, H. B.; Yang, E. H.; Lapetina, D.; Carr, M. S.; Yavorskyy, V.; Hague, J.; Aitchison, K. J.; How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? Frontiers in Genetics 2020, 11. https://www.frontiersin.org/article/10.3389/fgene.2020.491895DOI=10.3389/fgene.2020.491895
15. Genesight. Available online: https://genesight.com/product/ (accessed on 14 February 2022).
16. Genecept Assay. Available online: https://ncbi.nlm.nih.gov/gtr/tests/523653.4/ (accessed on 14 February 2022).
Review
For citations:
Linova L.P., Torgovtsev A.A., Limankin O.V., Nasyrova R.F. Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection. Personalized Psychiatry and Neurology. 2022;2(1):89-97. https://doi.org/10.52667/2712-9179-2022-2-1-89-97
Views:
674
Email this article 